JP2007500217A5 - - Google Patents

Download PDF

Info

Publication number
JP2007500217A5
JP2007500217A5 JP2006532922A JP2006532922A JP2007500217A5 JP 2007500217 A5 JP2007500217 A5 JP 2007500217A5 JP 2006532922 A JP2006532922 A JP 2006532922A JP 2006532922 A JP2006532922 A JP 2006532922A JP 2007500217 A5 JP2007500217 A5 JP 2007500217A5
Authority
JP
Japan
Prior art keywords
cells
composition
host
allogeneic
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006532922A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007500217A (ja
Filing date
Publication date
Priority claimed from US10/838,454 external-priority patent/US7435592B2/en
Application filed filed Critical
Publication of JP2007500217A publication Critical patent/JP2007500217A/ja
Publication of JP2007500217A5 publication Critical patent/JP2007500217A5/ja
Pending legal-status Critical Current

Links

JP2006532922A 2003-05-13 2004-05-11 同種異系細胞治療：ミラー効果 Pending JP2007500217A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47017103P 2003-05-13 2003-05-13
US54545004P 2004-02-18 2004-02-18
US54796604P 2004-02-26 2004-02-26
US54903204P 2004-03-01 2004-03-01
US10/838,454 US7435592B2 (en) 2003-05-13 2004-05-04 Compositions for allogeneic cell therapy
PCT/US2004/014589 WO2005001074A1 (en) 2003-05-13 2004-05-11 Allogeneic cell therapy: mirror effect

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010232031A Division JP6030819B2 (ja) 2003-05-13 2010-10-14 同種異系細胞治療：ミラー効果

Publications (2)

Publication Number Publication Date
JP2007500217A JP2007500217A (ja) 2007-01-11
JP2007500217A5 true JP2007500217A5 (https=) 2010-12-02

Family

ID=33425748

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2006532922A Pending JP2007500217A (ja) 2003-05-13 2004-05-11 同種異系細胞治療：ミラー効果
JP2010232031A Expired - Lifetime JP6030819B2 (ja) 2003-05-13 2010-10-14 同種異系細胞治療：ミラー効果
JP2011157205A Withdrawn JP2011225602A (ja) 2003-05-13 2011-07-15 同種異系細胞治療：ミラー効果
JP2014207763A Withdrawn JP2015028072A (ja) 2003-05-13 2014-10-09 同種異系細胞治療：ミラー効果
JP2016152801A Pending JP2016190868A (ja) 2003-05-13 2016-08-03 同種異系細胞治療：ミラー効果

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2010232031A Expired - Lifetime JP6030819B2 (ja) 2003-05-13 2010-10-14 同種異系細胞治療：ミラー効果
JP2011157205A Withdrawn JP2011225602A (ja) 2003-05-13 2011-07-15 同種異系細胞治療：ミラー効果
JP2014207763A Withdrawn JP2015028072A (ja) 2003-05-13 2014-10-09 同種異系細胞治療：ミラー効果
JP2016152801A Pending JP2016190868A (ja) 2003-05-13 2016-08-03 同種異系細胞治療：ミラー効果

Country Status (6)

Country Link
US (15) US7435592B2 (https=)
EP (1) EP1627054A1 (https=)
JP (5) JP2007500217A (https=)
CA (1) CA2525596C (https=)
IL (4) IL171850A (https=)
WO (1) WO2005001074A1 (https=)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US7402431B2 (en) * 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US20070025961A1 (en) * 2003-06-03 2007-02-01 Kenzo Bamba Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survival of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method of producing the same, gene encoding human monoclonal antibody and transf
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
EP2573166B1 (en) * 2004-02-26 2016-05-11 Immunovative Therapies, Ltd. Methods for preparing T-cells for cell therapy
HUE035726T2 (en) * 2004-03-01 2018-05-28 Immunovative Therapies Ltd Cell therapy formulation method and composition
US8865224B2 (en) * 2004-10-14 2014-10-21 Immunovative Therapies Ltd. Allogeneic cellular immunotherapy for opportunistic infection
GB0622400D0 (en) * 2006-11-10 2006-12-20 Avaris Ab Novel compositions and uses thereof
US9320794B2 (en) 2006-11-13 2016-04-26 Immunovative Therapies, Ltd. Ablative immunotherapy
US7972594B2 (en) 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
US20090232032A1 (en) * 2007-01-17 2009-09-17 Verbal World, Inc. Methods and Apparatus for the Manipulation of Conferenced Data
US20100325229A1 (en) * 2008-02-08 2010-12-23 Verbal World, Inc. Methods and Apparatus for Exchange of Electronic Communications
US20120128656A1 (en) * 2008-05-02 2012-05-24 Immunovative Therapies, Ltd. Vaccine compositions and methods
US9695397B2 (en) * 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
WO2009139921A2 (en) * 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
JP5725489B2 (ja) * 2008-06-27 2015-05-27 公立大学法人大阪市立大学 医療用組成物および医療用キット
US9283184B2 (en) 2008-11-24 2016-03-15 Massachusetts Institute Of Technology Methods and compositions for localized agent delivery
US8415150B2 (en) * 2009-02-24 2013-04-09 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (PML)
CN103002915B (zh) * 2010-04-13 2015-09-23 免疫创新治疗有限公司 抑制Treg细胞的方法和组合物
ES2686424T5 (es) * 2010-05-04 2023-03-27 Yeda Res & Dev Inmunoterapia con células alogénicas redireccionadas
WO2012011113A2 (en) 2010-07-22 2012-01-26 Shai Yarkoni Regulatory immune cells with enhanced targeted cell death effect
JP5006992B2 (ja) * 2010-08-06 2012-08-22 株式会社ケーナインラボ 免疫機能の強化剤
CN103068973A (zh) 2010-08-20 2013-04-24 免疫创新治疗有限公司 表达Th1特性和溶细胞性质的细胞
EP2471543A1 (en) 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
WO2012096974A1 (en) 2011-01-10 2012-07-19 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of allogeneic hematopoietic stem cell transplantation
CN107164330A (zh) * 2011-04-08 2017-09-15 贝勒医学院 使用嵌合细胞因子受体逆转肿瘤微环境的影响
WO2012151266A1 (en) 2011-05-03 2012-11-08 Michael Har-Noy Methods for handling biological drugs containing living cells
WO2012151279A2 (en) * 2011-05-03 2012-11-08 Michael Har-Noy Induction of il-12 using immunotherapy
RU2488356C1 (ru) * 2012-02-28 2013-07-27 Федеральное государственное бюджетное учреждение "Научный центр реконструктивной и восстановительной хирургии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НЦРВХ" СО РАМН) Способ коррекции иммунных нарушений
TWI676481B (zh) * 2012-05-02 2019-11-11 以色列商梵提夫免疫療法公司 使用免疫療法誘導ｉｌ－１２
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
CA2782942C (en) * 2012-07-12 2019-08-27 Canadian Blood Services Method for inducing immune tolerance using polymer-modified antigenic leukocytes
CN102809596B (zh) * 2012-08-21 2014-07-09 辉源生物科技（上海）有限公司 分离培养新生鼠皮层神经细胞记录t型钙通道电流的方法
US20140065096A1 (en) * 2012-09-05 2014-03-06 Regen BioPharma, Inc. Cancer therapy by ex vivo activated autologous immune cells
DK3019176T3 (da) 2013-07-12 2020-06-22 Canadian Blood Services Anvendelse af acellulære pro-inflammatoriske sammensætninger og fremgangsmåde til fremstilling heraf
EP3049114B1 (en) 2013-09-27 2021-11-10 Massachusetts Institute of Technology Carrier-free biologically-active protein nanostructures
BR112016015736B1 (pt) 2014-01-08 2022-01-04 Immunovative Therapies, Ltd. Uso de um aloantígeno, uma molécula que interage com receptor de superfície cd40 e citocinas tipo i; e pelo menos um ou mais antígenos de hiv, kit, composição e composição de avi
US10739353B2 (en) 2014-12-31 2020-08-11 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
CA2984794A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
CN108990413A (zh) 2015-08-12 2018-12-11 麻省理工学院 纳米颗粒的细胞表面偶联
JP7194020B2 (ja) 2015-10-22 2022-12-21 ジュノ セラピューティクス ゲーエムベーハー 細胞の培養方法ならびにそのためのキットおよび装置
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
JP7181517B2 (ja) * 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
JP2021523717A (ja) 2018-05-14 2021-09-09 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 代謝、生存、および機能を促進するための免疫細胞におけるａｒｉｄ５ｂ発現の操縦
JP7495137B2 (ja) * 2018-08-10 2024-06-04 ユーティレックス カンパニー リミテッド 癌抗原特異的細胞傷害性ｔ細胞
KR102234394B1 (ko) * 2019-03-08 2021-03-31 신지섭 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제
KR102216710B1 (ko) * 2019-03-27 2021-02-17 신지섭 Nk세포배양배지용 첨가조성물, 상기 첨가조성물을 이용한 nk세포배양방법 및 상기 배양방법으로 얻어진 피부트러블개선용 화장료조성물
US12605463B2 (en) 2019-04-12 2026-04-21 The Johns Hopkins University Tolerogenic artificial antigen-presenting cells
US11246906B2 (en) 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
KR20230016178A (ko) 2020-04-15 2023-02-01 엘커메스 파마 아일랜드 리미티드 혈관신생 억제제와 조합된 면역자극제
WO2025221890A1 (en) * 2024-04-16 2025-10-23 Mirror Biologics, Inc. Methods and compositions for improving the immune response against viral pathogens

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
AU5729294A (en) 1992-11-25 1994-06-22 Tanox Biosystems, Inc. Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
IL107483A0 (en) * 1993-11-03 1994-02-27 Yeda Res & Dev Bone marrow transplantation
AU5930396A (en) * 1995-05-25 1996-12-11 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
CA2227327A1 (en) * 1995-07-25 1997-02-13 Celltherapy, Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
ATE347588T1 (de) 1996-05-23 2006-12-15 Scripps Research Inst Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten
CA2309206A1 (en) * 1997-11-10 1999-05-20 Arch Development Corporation Methods for treatment of tumors and tumor cells using ex vivo activated t cells
US6558662B2 (en) 1997-11-14 2003-05-06 The General Hospital Corporation Treatment of hematologic disorders
DE69928407T2 (de) 1998-07-30 2006-08-03 Regents Of The University Of Minnesota, Minneapolis Ex vivo behandlung von allogenen und xenogenen t-zellen mit gp39-antagonisten
US20030119185A1 (en) 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US20020127208A1 (en) * 2000-08-31 2002-09-12 Waller Edmund K. Method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
US20040258661A1 (en) 2001-10-31 2004-12-23 Daniel Fowler Generation of use of tc1 and tc2 cells
JP2004538331A (ja) * 2001-08-17 2004-12-24 ロジャー ウィリアムス ホスピタル インサイチュ免疫法
US20030134415A1 (en) 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
DE10230223A1 (de) 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
EP2573166B1 (en) 2004-02-26 2016-05-11 Immunovative Therapies, Ltd. Methods for preparing T-cells for cell therapy
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
US8865224B2 (en) * 2004-10-14 2014-10-21 Immunovative Therapies Ltd. Allogeneic cellular immunotherapy for opportunistic infection
WO2007120128A1 (en) 2006-04-13 2007-10-25 Immunovative Therapies, Ltd. Allogeneic cell therapy for treatment of opportunistic infection
US7972594B2 (en) * 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy

Similar Documents

Publication Publication Date Title
JP6030819B2 (ja) 同種異系細胞治療：ミラー効果
JP2007500217A5 (https=)
TW200403340A (en) Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
JP2017061558A (ja) Ｔｈ１特性と細胞溶解性を発現する細胞
HK1257638A1 (en) Cells expressing th1 characteristics and cytolytic properties
HK1184498A (en) Cells expressing th1 characteristics and cytolytic properties